PAR stops vaccination with AstraZeneca vaccine

PAR Health Minister Zweli Mkhize said the vaccine’s effectiveness in preventing more severe forms of the disease could not be studied either, as the average age of the demographic that was vaccinated with AstraZeneca was 31 years.

Last weekend, a UK and Swedish company realized that its coronavirus vaccine, developed in collaboration with the University of Oxford, only partially protects against a mild form of the coronavirus strain found in PAR . The study, which involved about 2,000 people, was conducted by the University of Whitwatersand in Johannesburg. Your data has not yet been carefully analyzed.

Minister Mkhize said the country’s government will await further recommendations on how to proceed with the AstraZeneca vaccine. PAR received around 1 million. doses of the vaccine and is set to be widely used this week, the BBC reports.

Prof. Sarah Gilbert, an Oxford vaccine collector, says the vaccine will likely need to be modified to be effective against a strain of coronavirus that spreads PAR, also known as 501.V2 or B.1.351. Although, according to her, the current vaccine should protect against serious diseases.

Experts say vaccines can be redesigned and improved in a matter of weeks or months to make them more effective against new strains of the virus.

The Early Modern results suggest that the vaccine remains effective against the PAR variant. AstraZeneca said its vaccine provides good protection against the common strain of COVID-19 in the UK. The first results suggest that a vaccine developed by Pfizer and BioNTech protects against a new variant of the virus.

PAR expects to receive vaccines from Pfizer and Johnson & Johnson soon. The latter company, like ra V, presented clinical trials of its vaccine at the end of January, which shows an efficacy of 66% and acts by protecting the body against moderate to severe coronavirus. Unlike other manufacturers, a Johnson & Johnson vaccine is sufficient to protect immunity.

Rayti komentar